Cogent Biosciences, Inc. COGT Proceeds From Convertible Senior Notes
Proceeds From Convertible Senior Notes at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept cogt:ProceedsFromConvertibleSeniorNotes.
The official record: Cogent Biosciences, Inc.’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cogent Biosciences, Inc.'s proceeds from convertible senior notes.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Cogent Biosciences, Inc.'s proceeds from convertible senior notes?
- Cogent Biosciences, Inc. (COGT) reported proceeds from convertible senior notes of $55.78M in Q4 2025.
- What does proceeds from convertible senior notes mean?
- Represents the total cash inflows received from the issuance of debt instruments that grant the holder the option to convert the debt into equity under specified conditions. This serves as a strategic capital-raising mechanism that balances debt financing with potential future equity dilution. Investors analyze this to evaluate the company's leverage profile and long-term capital structure strategy.